drugset / Trial / NCT03698227
OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
Phase 2
Terminated
2 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NaSingle-groupOpen-labelTreatment
Summary
This is an exploratory, prospective, open label, single arm, phase II-study for the evaluation of efficacy and feasibility (as determined by safety and tolerability) of olaratumab and doxorubicin rechallenge in anthracycline pretreated locally advanced (unresectable) or metastatic soft tissue sarcoma patients.
Timeline
- Start
- 2018-11-12
- Primary completion
- 2020-06-25
- Completion
- 2020-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Olaratumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Dexrazoxane | Small molecule | 750 mg/m2 | Intravenous |